Disease · MONDO_0020283

uveitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. uveitis. Diseases, record MONDO_0020283. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020283

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: uveitis; Open Targets
Open Targets ID: MONDO_0020283; Open Targets
Other names: inflammation of uvea, uvea inflammation, uveitis (disease); Open Targets
Disease Ontology: DOID:13141; Disease Ontology
MeSH: D014605; MeSH
NCI Thesaurus: C26909; NCI Thesaurus
Orphanet: ORPHA:98715; Orphanet
Highest stage of its drugs: Approval, for 6 of its 60 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs60

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ADALIMUMAB	CHEMBL1201580	Antibody	Approval	EMA Human Drugs and PMDA	28	13	13	Drugs and targets
FLUOCINOLONE ACETONIDE	CHEMBL989	Small molecule	Approval	DailyMed	11	9	9	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	EMA Human Drugs	7	6	4	Drugs and targets
METHYLPREDNISOLONE ACETATE	CHEMBL1364144	Small molecule	Approval	DailyMed	2	1	0	Drugs and targets
PREDNISOLONE SODIUM PHOSPHATE	CHEMBL1201014	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
HOMATROPINE METHYLBROMIDE	CHEMBL1200851	Small molecule	Approval	TTD	1	0	0	Drugs and targets
GEVOKIZUMAB	CHEMBL1743026	Antibody	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
SECUKINUMAB	CHEMBL1743068	Antibody	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
SIROLIMUS	CHEMBL413	Small molecule	Phase 3	TTD	5	3	3	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 60

See all 60 drugs

Targets53

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	14	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
TNF	Tumor necrosis factor	4	TNF-alpha inhibitor	Approval	https://conductscience.org/library/genes/7124	Drugs and targets
JAK1	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 2	https://conductscience.org/library/genes/3716	Drugs and targets
TYK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor	Phase 2	https://conductscience.org/library/genes/7297	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	2	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	2	Interferon alpha/beta receptor agonist	Phase 3	https://conductscience.org/library/genes/3455	Drugs and targets
IL17A	Interleukin-17A	2	Interleukin 17A inhibitor	Phase 3	https://conductscience.org/library/genes/3605	Drugs and targets
IL2RA	Interleukin-2 receptor	2	Interleukin-2 receptor binding agent; Interleukin-2 receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3559	Drugs and targets
IL2RB	Interleukin-2 receptor	2	Interleukin-2 receptor binding agent; Interleukin-2 receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3560	Drugs and targets

1 to 10 of 53

See all 53 targets

Trials86

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00333814	A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis	Phase 2/3	229	2011-04-14	Intermediate Uveitis, Posterior Uveitis	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT01829295	Methotrexate and Mycophenolate Mofetil for UVEITIS	Phase 3	216	2019-04-26	Uveitis	METHOTREXATE, MYCOPHENOLATE MOFETIL	Its record names the disease	ClinicalTrials.gov
NCT02623426	Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial	Phase 3	194	2023-07-10	Uveitis, Macular Edema	DEXAMETHASONE, METHOTREXATE, RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02746991	Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis	Phase 3	153	2020-07-07	Posterior Uveitis, Intermediate Uveitis, Panuveitis	FLUOCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT00995709	Phase III Study in Refractory Behcet's Disease	Phase 3	118	2015-08-31	Behcet Disease	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT01805323	A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema		101	2014-05-30	Macular Edema	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT01090310	Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis	Phase 3	86	2016-01-14	Non-infectious Uveitis	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT01232920	First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial	Phase 3	80	2016-01-05	Uveitis	METHOTREXATE, MYCOPHENOLATE MOFETIL	Its record names the disease	ClinicalTrials.gov
NCT03207815	Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis	Phase 2	74	2022-01-21	Noninfectious Uveitis	FILGOTINIB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00525902	Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis	Phase 2	31	2012-04-09	Uveitis	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 86

See all 86 trials

Comparisons in its trials15

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Methotrexate vs Mycophenolate Mofetil: deaths from any cause	1 of 107	0 of 109	216	NCT01829295	Trial comparisons
Methotrexate vs Mycophenolate Mofetil: serious adverse events	7 of 107	7 of 109	216	NCT01829295	Trial comparisons
Methotrexate vs Mycophenolate Mofetil: Number of Participants Achieving Treatment Success at 6 Months (Phase I, 0-6 Months)	64 of 96	56 of 98	194	NCT01829295	Trial comparisons
FAI Insert vs Sham Injection: Number of Participants With Recurrence of Uveitis in Study Eye Within 36 Months	47 of 101	39 of 52	153	NCT02746991	Trial comparisons
FAI Insert vs Sham Injection: Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months	22 of 101	28 of 52	153	NCT02746991	Trial comparisons
FAI Insert vs Sham Injection: deaths from any cause	0 of 101	0 of 52	153	NCT02746991	Trial comparisons
FAI Insert vs Sham Injection: serious adverse events	21 of 101	7 of 52	153	NCT02746991	Trial comparisons
Methotrexate vs Mycophenolate Mofetil: Number of Participants Achieving Treatment Success at 12 Months on Same Medication (Phase I, 6-12 Months)	48 of 60	40 of 54	114	NCT01829295	Trial comparisons
Methotrexate vs Mycophenolate Mofetil: serious adverse events	0 of 41	1 of 39	80	NCT01232920	Trial comparisons
Filgotinib vs Placebo: deaths from any cause	0 of 38	0 of 36	74	NCT03207815	Trial comparisons

1 to 10 of 15

See all 15 comparisons in its trials

Papers from its trials39

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37294447	RESULT	1	PubMed
36749914	RESULT	1	PubMed
36701644	RESULT	1	PubMed
35143800	RESULT	1	PubMed
35085661	RESULT	1	PubMed
33675850	RESULT	1	PubMed
32779952	RESULT	1	PubMed
31503307	RESULT	1	PubMed
29471416	RESULT	1	PubMed
29370572	RESULT	2	PubMed

1 to 10 of 39

See all 39 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020283

GET https://conductscience.org/api/diseases/v1/MONDO_0020283/drugs?page=2

API reference For AI assistants